Reported 6,488 shares, down 306 (4.5%) from the prior quarter.
Reported value -45.0%; share count -4.5% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 141000 |
| 2022-03-31 | 160000 |
| 2022-06-30 | 88000 |
| 2022-09-30 | 142000 |
| 2022-12-31 | 131154 |
| 2023-03-31 | 81294 |
| 2023-06-30 | 261214 |
| 2023-09-30 | 231343 |
| 2023-12-31 | 258492 |
| 2024-03-31 | 852224 |
| 2024-06-30 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q2 2024 | Reduced | 0 | -19,764 (-100.0%) | 0 | $0 | 2024-08-13 | |
| Q1 2024 | Added | 19,764 | +2,957 (17.6%) | < 0.01% | $852,224 | 2024-05-13 | |
| Q4 2023 | Reduced | 16,807 | -67 (-0.4%) | < 0.01% | $258,492 | 2024-02-13 | |
| Q3 2023 | Added | 16,874 | +599 (3.7%) | < 0.01% | $231,343 | 2023-11-13 | |
| Q2 2023 | Added | 16,275 | +5,799 (55.4%) | < 0.01% | $261,214 | 2023-08-04 | |
| Q1 2023 | Added | 10,476 | +3,698 (54.6%) | < 0.01% | $81,294 | 2023-05-12 | |
| Q4 2022 | Added | 6,778 | +127 (1.9%) | < 0.01% | $131,154 | 2023-02-10 | |
| Q3 2022 | Added | 6,651 | +163 (2.5%) | < 0.01% | $142,000 | 2022-11-14 | |
| Q2 2022 | Reduced | 6,488 | -306 (-4.5%) | < 0.01% | $88,000 | 2022-08-12 | |
| Q1 2022 | Added | 6,794 | +1,535 (29.2%) | < 0.01% | $160,000 | 2022-05-13 | |
| Q4 2021 | Added | 5,259 | +1,392 (36.0%) | < 0.01% | $141,000 | 2022-02-11 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
56 managers reported VERA THERAPEUTICS INC for Q2 2022.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| FMR LLC | Added | 4,015,351 | +3,321 | < 0.01% | $54,648,928 | 5 qtrs |
| Sofinnova Investments Inc | Unchanged | 3,181,442 | 0 | 3.61% | $43,299,000 | 5 qtrs |
| Abingworth LLP | Unchanged | 2,960,231 | 0 | 12.9% | $40,289,000 | 5 qtrs |
| CITADEL ADVISORS LLC | Added | 2,122,851 | +33,331 | < 0.01% | $28,892,000 | 5 qtrs |
| RA CAPITAL MANAGEMENT L P | Reduced | 1,578,820 | -387,264 | 0.57% | $21,488,000 | 2 qtrs |
| Kynam Capital Management LP | Added | 1,522,712 | +1,020,384 | 5.29% | $20,724,000 | 3 qtrs |
| BlackRock Inc | Added | 717,034 | +37,359 | < 0.01% | $9,759,000 | 5 qtrs |
| VANGUARD GROUP INC | Added | 676,937 | +58,934 | < 0.01% | $9,214,000 | 5 qtrs |
| Vivo Capital LLC | Unchanged | 666,666 | 0 | 0.91% | $9,073,000 | 2 qtrs |
| Octagon Capital Advisors LP | Unchanged | 575,000 | 0 | 2.09% | $7,826,000 | 5 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2022
- Filed
- August 12, 2022
- Filing type
- 13F-HR
- Position type
- CL A
Voting authority reported
- Sole
- 6,488
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.